Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Solu-Medrol

(Methylprednisolone Sodium Succinate)

Phase 3Small molecule

MMassachusetts Eye and Ear Infirmary

It's a strong anti-inflammatory steroid used to reduce swelling and suppress the immune system in serious conditions like severe allergies, autoimmune diseases, organ transplant rejection, and certain types of cancer. It works quickly when given by injection to help the body calm down its overactive inflammatory response.[1] Solu-Medrol is currently being investigated across 14 indications[3], with its most advanced program in Phase 3.[1]

Solu-Medrol is one of 359 small molecule programs targeting Type III Hypersensitivity Reaction Disease. It is currently in Phase 3.

14

Indications

23

Total Trials

6

Active Trials

358

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type III Hypersensitivity Reaction DiseaseUnknown

StrokeRecruiting

LymphomaUnknown

LeukemiaUnknown

AnemiaUnknown

DermatitisUnknown

Rheumatoid ArthritisUnknown

Ulcerative ColitisActive, not recruiting

Multiple SclerosisUnknown

AsthmaUnknown

Type III Hypersensitivity Reaction DiseasePreclinical

Unknown

StrokePhase 3

Recruiting

LymphomaPreclinical

Unknown

LeukemiaPreclinical

Unknown

AnemiaPreclinical

Unknown

DermatitisPreclinical

Unknown

Rheumatoid ArthritisPreclinical

Unknown

Ulcerative ColitisPreclinical

Active, not recruiting

Multiple SclerosisPreclinical

Unknown

AsthmaPreclinical

Unknown

Showing 10 of 14 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Zofran

Cabenuva

Norvir

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Kenalog

BBausch Health Americas, Inc.

Nuvigil

NNuvo Research GmbH

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Headaches Associated With Subarachnoid Hemorrhage (SAH)

NCT07054801

Q3 2027

Phase 3Recruiting

Stroke

NCT07202143

Q4 2027

Phase 2Recruiting

Agvhd

NCT07185633

Q4 2029

N/ANot yet recruiting

Ischemic Stroke

NCT07175649

PreclinicalNot yet recruiting

Knee Osteoarthritis

NCT07703280

Clinical

Trials by Indication[1]

Stroke2 trials

Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke

Active, not recruiting·WWan-Jin Chen·Phase 3·NCT06360458·928 enrolled

Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia

Recruiting·YYiLin·Phase 3·NCT07202143·200 enrolled

Deafness1 trial

Sudden Deafness Treatment Trial

Completed·MMassachusetts Eye and Ear Infirmary·Phase 3·NCT00097448·255 enrolled

Ischemic stroke1 trial

Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT07175649·912 enrolled

Conditioning1 trial

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Terminated·SStanford University·Phase 3·NCT00568633·58 enrolled

Injury1 trial

Corticosteroids and Myocardial Injury in CAP (COLOSSEUM TRIAL)

Unknown status·UUniversity of Roma La Sapienza·Phase 3·NCT03745664·122 enrolled

17 more indications

COVID-191 trial

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

Terminated·HHospital Sao Domingos·Phase 2·NCT04377503·30 enrolled

Epilepsy1 trial

Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy

Unknown status·LLouisiana State University Health Sciences Center in New Orleans·Phase 1/2·NCT04219995·10 enrolled

Alopecia Areata1 trial

Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata

Completed·KKing Saud University·Phase 4·NCT01167946·42 enrolled

Pneumonia1 trial

Sphingosine-1-phosphate and Pneumonia

Unknown status·TTaipei Medical University WanFang Hospital·Phase 2/3·NCT04007328·400 enrolled

Graft Versus Host Disease1 trial

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

Completed·MMassachusetts Eye and Ear Infirmary·Phase 1·NCT01977781·40 enrolled

Severe Acute Respiratory Syndrome1 trial

Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19

Completed·FFundação de Medicina Tropical Dr. Heitor Vieira Dourado·Phase 2·NCT04343729·416 enrolled

Hip Fracture1 trial

Preoperative Single Glucocorticoid Hip Fracture Hip Fracture Surgery

Completed·HHvidovre University Hospital·Phase 4·NCT02317601·122 enrolled

Asthma1 trial

Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients

Completed·HHamamatsu University·Phase 4·NCT00627731·50 enrolled

Glucocorticoids1 trial

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02798523·33 enrolled

Acute Lymphoblastic Leukemia1 trial

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02779283·7 enrolled

Acute Respiratory Distress Syndrome1 trial

Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome

Completed·NNational Cancer Center, Korea·Phase 2·NCT00290602·40 enrolled

Acute Graft Versus Host Disease1 trial

Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract

Withdrawn·WWake Forest University Health Sciences·Phase 2·NCT02425813

Total Knee Replacement1 trial

Pre-operative Intravenous Steroid in Total Knee Replacement for Pain Relief and Recovery

Completed·QQueen Elizabeth Hospital, Hong Kong·Phase 4·NCT03082092·60 enrolled

Headache1 trial

Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1

Completed·TThe Cooper Health System·Phase 1·NCT06462781·10 enrolled

aGVHD1 trial

A Prospective, Single-Arm, Phase II Clinical Study of Gecacitinib-Corticosteroids as First-Line Treatment for Grade II-IV Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·BBin Gu·Phase 2·NCT07185633·25 enrolled

Knee Osteoarthritis1 trial

Peripheral-blood Cell Purification for PBMCs (PCP-PBMCs) Injection for Knee Osteoarthritis (PCP-PBMCs-KOA)

Not yet recruiting·DDuoGenic StemCells Corporation (DGSC)·Preclinical·NCT07703280·240 enrolled

Headaches Associated With Subarachnoid Hemorrhage (SAH)1 trial

Intra-arterial Lidocaine and Methylprednisolone Injection Into the Middle Meningeal Artery For Treatment of Headache Associated With Subarachnoid Hemorrhage

Recruiting·DDaniel Raper, MBBS·Phase 2·NCT07054801·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Methylprednisolone Sodium Succinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methylprednisolone Sodium Succinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methylprednisolone Sodium Succinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts Eye and Ear Infirmary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMassachusetts Eye and Ear Infirmary

Related News